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Essentials
• Factor XI (FXI) deficient mice have normal hemostasis in a tail transection model.
• The hemostatic capacity of FXI À/À mice was assessed in three different bleeding models.
• FXI À/À mice have increased saphenous vein bleeding.
• FXI À/À mice may be a useful experimental model to study bleeding associated with FXI deficiency.
Summary. Background: Factor XI (FXI) is a key component of the intrinsic pathway of coagulation. It can be activated by either FXIIa or thrombin and amplifies thrombin generation during clot formation. Congenital FXI deficiency in humans (known as hemophilia C) is associated with bleeding after hemostatic challenge. However, to date there are no reports of excess bleeding in FXI-deficient mice. Objectives: To determine if the absence of FXI in mice prolongs bleeding in different models. Methods: We assessed the hemostatic capacity of FXI À/À mice in three different bleeding models: tail bleeding, surgical bleeding and saphenous vein bleeding. Results: We found that tail bleeding and surgical bleeding of FXI À/À mice were similar to wild-type mice.
However, FXI À/À mice had an impaired hemostatic capacity in the saphenous vein bleeding model compared with wild-type controls. Conclusions: Our results indicate that FXI À/À mice have a mild hemostatic defect after
Introduction
Hemostasis is a complex process that is essential to prevent excessive blood loss from the vasculature at the site of vascular injury by formation of a platelet-fibrin clot. Blood coagulation can be activated by either the tissue factor (TF)/factor VIIa (FVIIa) complex or by factor XIIa (FXIIa) [1, 2] . The TF/FVIIa complex is essential for hemostasis but also can drive thrombosis [1] . In contrast, FXIIa does not play a role in hemostasis but can trigger thrombosis [2] . Factor XI (FXI) is activated by both FXIIa and thrombin and plays a role in both hemostasis and thrombosis in humans by amplifying thrombin generation and fibrin formation [2] . FXI deficiency in humans is a rare bleeding disorder referred to as hemophilia C. These patients rarely bleed spontaneously but exhibit excessive bleeding after hemostatic challenge, such as surgery or trauma in certain tissues (e.g. dental surgery, tonsillectomy, prostate surgery or in the postpartum period) [3] [4] [5] . It is notable that bleeding associated with FXI deficiency frequently occurs in tissues with a high fibrinolytic activity, such as the urinary tract and oropharynx [3, 4] . This may be because clots formed in the absence of FXI are more susceptible to fibrinolysis [6] [7] [8] . Furthermore, the clinical bleeding phenotype in humans with FXI deficiency is highly variable and correlates poorly with FXI levels [3] [4] [5] . To date no hemostatic defects have been reported in FXI À/À mice using a tail transection model [9] [10] [11] [12] .
Epidemiological studies in humans found an increased risk of venous thromboembolism associated with elevated FXI levels [13] . Consistent with this prothrombotic role of FXI, FXI À/À mice have reduced thrombosis in a variety of models [11, 12, 14, 15] . This has led to an interest in targeting FXI to prevent thrombosis [15] [16] [17] . Therapeutic strategies targeting FXI and FXIa have been developed for reducing thrombosis, which include inhibitory antibodies, small molecule inhibitors or antisense oligonucleotides that reduce FXI levels (FXI-ASO) [15, 16] . A recent proof of concept study compared FXI-ASO to conventional anticoagulation with enoxaparin for prevention of venous thromboembolism in patients undergoing total knee replacement surgery [17] . Importantly, lowering FXI levels was associated with a reduction in venous thromboembolism without increasing the risk of bleeding.
Here, we report that FXI À/À mice exhibited a significant increase in bleeding in the saphenous vein model. However, the increase in bleeding was milder than in FIX À/À mice (hemophilia B). Therefore, FXI À/À mice may be a good model of bleeding associated with FXI deficiency or pharmacologic inhibition. termates. Genotyping of mice was performed as described [11, 12] . We used 6-to 10-week-old male mice. In addition, we used hemophilia B (FIX-deficient [FIX
Material and methods

Mice
]) mice on a C57BL/6J background [18] and in some experiments we used wild-type (WT) control C57Bl/6J mice from an in-house breeding colony. The Animal Care and Use Committee of our institution approved all mouse experiments.
Tail bleeding time
Mice were anesthetized with pentobarbital (intraperitoneal injection, 50 mg per kg) and put on a 37°C heating pad. After 5 min of warming the tail was transected with a disposable surgical blade 4 mm from the tip of the mouse tail. After transection the tail was placed in a 15-mL falcon tube filled with saline (warmed to 37°C) and the time to cessation of bleeding was recorded.
Abdominal wall bleeding model
Mice were anesthetized with 3.0% Isoflurane (Piramal Healthcare, Medak, India). The ventral abdominal skin and linea alba were cut with scissors ( Fig. 1A) and a stainless-steel blade was inserted under the right side of the abdominal musculature to serve as a platform support (Fig. 1B) . A razor blade was used to make a lateral incision in the muscle from a point 6 mm from the midline all the way to the midline incision at a 90°angle to the linea alba incision (Fig. 1C) . The picture shows bleeding 30 s after the cut. At 1 min and every 2 min for 19 min filter paper was placed on the cut surfaces for 10 s. Blood was extracted from the filter paper using red blood lysis buffer (Alfa Aesar, Ward Hill, MA, USA) overnight at room temperature. Samples were transferred to a 96-well plate (Denville Scientific Inc., Holliston, MA, USA) and the absorbance at 440 nm was measured using a spectrophotometer (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA).
Saphenous vein bleeding model
We used the saphenous bleeding model as previously described [19] . Under observation with an operating microscope, the saphenous vein was exposed and first partially transected with microscissors followed by a small longitudinal cut. When the bleeding ceased, the formed clot was physically dislodged with the sharp tip of a 30-gauge needle, and dislodgement was repeated after each incidence of hemostasis over the course of 30 min. The total number of clots formed (hemostatic events) within a 30-min period was recorded. In this model, higher numbers of reforming clots correspond to better hemostatic control/capacity.
Measurement of blood cells
The number of circulating red and white blood cells and platelets was measured using a Hemavet Ò machine (Drew Scientific Inc., Miami Lakes, FL, USA).
Statistics
Descriptive statistics were applied for analysis of results and data presented as median and interquartile range ([IQR] 25th to 75th percentile). Differences between two groups were analyzed by the Mann-Whitney test. In the saphenous vein bleeding model, differences between the FXI À/À , FIX À/À and wild-type mice were tested by one-way analysis of variance (ANOVA) and Bonferroni correction for multiple testing. Statistical analyses were performed with Graph Pad PRISM software (La Jolla, CA, USA). A P-value < 0.05 was considered to be significant.
Results and discussion
The tail transection model is the most commonly used method in experimental mouse studies to assess a bleeding propensity in hypocoagulable states, including coagulation defects and evaluation of different anticoagulant treatments [20] . The principle of this method is that the time to cessation of bleeding after tail transection is used to assess hemostasis. As both coagulation and platelets contribute to hemostasis in this model, we measured circulating blood cells and platelets. There were no differences in red and white blood cells or platelets in WT and FXI (Fig. 2) . These results are consistent with previous studies [9] [10] [11] [12] . However, as previously demonstrated, mice exhibited some variation in bleeding time [9, 12] We performed a second model that involved transection of blood vessels in the abdominal wall. However, similar to the tail transection model, we did not observe any differences in bleeding between FXI À/À and WT littermate mice (Fig. 3) . The investigator was blinded to the genotypes of the mice. Finally, we examined FXI À/À mice in the saphenous vein bleeding model [19] . WT and FIX À/À mice Blood at the cut surface was absorbed onto filter paper placed on the cut at 1 min and every 2 min for a total of 19 min. Wild-type (n = 7) and FXI À/À (n = 8) littermate mice were examined. Blood was extracted from the filter paper and the color quantified by measuring the absorbance at 440 nm. The median of each group is shown. The data were analyzed using the non-parametric MannWhitney test to detect differences between the two groups.
(hemophilia B) served as normal and hypocoagulable controls. We observed a mild but significantly impaired hemostatic capacity in FXI , respectively, P < 0.001) (Fig. 4A) . We repeated the experiments with littermate mice generated from crosses between FXI +/À mice. Consistent with the results shown in Fig. 4(A) , there was a significant difference in the number of hemostatic events between FXI À/À mice and WT littermates (Fig. 4B) . FXI +/À mice had an intermediate number of hemostatic events but this group was not statistically different from the other two groups (Fig. 4B ).
There are a number of different bleeding models used in mice that include tail bleeding, saphenous vein bleeding and laser injury of arterioles in the cremaster muscle [21] . The saphenous vein bleeding model was designed as a general hemostasis model to detect bleeding tendencies and was first tested in FVIII À/À mice [19] . There are several important differences between the saphenous vein model and the tail bleeding model. The tail bleeding model typically involves transection of both an artery and veins. Vessel transection induces vasoconstriction that is a protective response to reduce blood loss. Defects in the hemostatic system are associated with prolonged bleeding times in this model. In addition, formation of unstable clots can lead to spontaneous re-bleeding. By contrast, the saphenous vein model involves a punch injury without transection. Interestingly, recombinant FVIII had no effect on a punch injury alone and a small scissor cut was added to the model [19] . The other important feature about the saphenous vein model is that it involves repeated disruptions of the clot. This more directly tests the stability of the clot and time for the hemostatic system to re-form clots. In addition, by including the rebleeding challenge repeatedly over a 30-min time course, a better assessment of the average hemostatic time is obtained for each animal (e.g. 15 hemostatic events over 30 min yields a 2-min average time, which can vary from 40 to 180 or more seconds throughout the 30-min interval). Therefore, this model is more likely to detect subtle defects in the hemostatic system, such as FXI deficiency or pharmacologic inhibition of FXI. Although the experimental data from mice do not necessarily extrapolate to humans, it is interesting to note that bleeding in FXI-deficient patients occurs mostly as a result of a hemostatic challenge due to traumatic or surgical injuries. We conclude that FXI À/À mice have an increase in bleeding after injury of the saphenous vein and represent a good model for studying the bleeding disorder associated with FXI deficiency or pharmacologic inhibition of FXI. 
